Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?
In the current worldwide pandemic situation caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the newest coronavirus disease (COVID-19), therapeutics and prophylactics are urgently needed for a large population. Some of the prophylaxis strategies are based on the development of antibodies targeting viral proteins. IgY antibodies are a type of immunoglobulin present in birds, amphibians, and reptiles. They are usually obtained from egg yolk of hyper-immunized hens and represent a relatively inexpensive source of antibodies. Specific IgY can be produced by immunizing chickens with the target antigen and then purifying from the egg yolk. Chicken IgY has been widely explored as a clinical anti-infective material for prophylaxis, preventive medicine, and therapy of infectious diseases. Administered non-systemically, IgY antibodies are safe and effective drugs. Moreover, passive immunization with avian antibodies could become an effective alternative therapy, as these can be obtained relatively simply, cost-efficiently, and produced on a large scale. Here, we highlight the potential use of polyclonal avian IgY antibodies as an oral prophylactic treatment for respiratory viral diseases, such as COVID-19, for which no vaccine is yet available
Main Authors: | , , , , |
---|---|
Other Authors: | |
Format: | artículo biblioteca |
Language: | English |
Published: |
Multidisciplinary Digital Publishing Institute
2020-08-28
|
Subjects: | Anti-infective agents, Immune therapy, Vaccine, Antibodies, Epitope, Peptide, |
Online Access: | http://hdl.handle.net/10261/219966 http://dx.doi.org/10.13039/501100000780 http://dx.doi.org/10.13039/501100004837 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
dig-ipna-es-10261-219966 |
---|---|
record_format |
koha |
spelling |
dig-ipna-es-10261-2199662022-12-30T11:39:35Z Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19? Baca-González, Victoria Asensio-Calavia, Patricia González-Acosta, Sergio Morales-delaNuez, Antonio Pérez de Lastra, José Manuel European Commission Cabildo de Tenerife Ministerio de Ciencia e Innovación (España) Baca-González, Victoria [0000-0001-7195-7211] Asensio-Calavia, Patricia [0000-0001-8413-8426] Morales-delaNuez, Antonio [0000-0002-0184-2037] Anti-infective agents Immune therapy Vaccine Antibodies Epitope Peptide In the current worldwide pandemic situation caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the newest coronavirus disease (COVID-19), therapeutics and prophylactics are urgently needed for a large population. Some of the prophylaxis strategies are based on the development of antibodies targeting viral proteins. IgY antibodies are a type of immunoglobulin present in birds, amphibians, and reptiles. They are usually obtained from egg yolk of hyper-immunized hens and represent a relatively inexpensive source of antibodies. Specific IgY can be produced by immunizing chickens with the target antigen and then purifying from the egg yolk. Chicken IgY has been widely explored as a clinical anti-infective material for prophylaxis, preventive medicine, and therapy of infectious diseases. Administered non-systemically, IgY antibodies are safe and effective drugs. Moreover, passive immunization with avian antibodies could become an effective alternative therapy, as these can be obtained relatively simply, cost-efficiently, and produced on a large scale. Here, we highlight the potential use of polyclonal avian IgY antibodies as an oral prophylactic treatment for respiratory viral diseases, such as COVID-19, for which no vaccine is yet available We are grateful to current projects APOGEO (INTERREGMAC Call-European Funds for Regional Development-FEDER) and Immunowine (funded by the Cabildo de Tenerife, under the TFinnova Programme supported by MEDI and FDCAN funds, project number 19-0231) for providing financial support for the research into innovative applications of IgY-technology. V.B.-G. is the recipient of a contract for APOGEO project. A.M.-d. is the recipient of a postdoctoral contract for Immunowine project. P.A.-C. is the recipient of an aid for the Contracts of Technical Support Personnel (PTA) from the Spanish Ministry of Science and Innovation. Peer reviewed 2020-09-21T13:12:01Z 2020-09-21T13:12:01Z 2020-08-28 artículo http://purl.org/coar/resource_type/c_6501 Vaccines 8(3): 486 (2020) http://hdl.handle.net/10261/219966 10.3390/vaccines8030486 2076-393X http://dx.doi.org/10.13039/501100000780 http://dx.doi.org/10.13039/501100004837 32872186 en Publisher's version https://doi.org/10.3390/vaccines8030486 Sí open Multidisciplinary Digital Publishing Institute |
institution |
IPNA ES |
collection |
DSpace |
country |
España |
countrycode |
ES |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-ipna-es |
tag |
biblioteca |
region |
Europa del Sur |
libraryname |
Biblioteca del IPNA España |
language |
English |
topic |
Anti-infective agents Immune therapy Vaccine Antibodies Epitope Peptide Anti-infective agents Immune therapy Vaccine Antibodies Epitope Peptide |
spellingShingle |
Anti-infective agents Immune therapy Vaccine Antibodies Epitope Peptide Anti-infective agents Immune therapy Vaccine Antibodies Epitope Peptide Baca-González, Victoria Asensio-Calavia, Patricia González-Acosta, Sergio Morales-delaNuez, Antonio Pérez de Lastra, José Manuel Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19? |
description |
In the current worldwide pandemic situation caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the newest coronavirus disease (COVID-19), therapeutics and prophylactics are urgently needed for a large population. Some of the prophylaxis strategies are based on the development of antibodies targeting viral proteins. IgY antibodies are a type of immunoglobulin present in birds, amphibians, and reptiles. They are usually obtained from egg yolk of hyper-immunized hens and represent a relatively inexpensive source of antibodies. Specific IgY can be produced by immunizing chickens with the target antigen and then purifying from the egg yolk. Chicken IgY has been widely explored as a clinical anti-infective material for prophylaxis, preventive medicine, and therapy of infectious diseases. Administered non-systemically, IgY antibodies are safe and effective drugs. Moreover, passive immunization with avian antibodies could become an effective alternative therapy, as these can be obtained relatively simply, cost-efficiently, and produced on a large scale. Here, we highlight the potential use of polyclonal avian IgY antibodies as an oral prophylactic treatment for respiratory viral diseases, such as COVID-19, for which no vaccine is yet available |
author2 |
European Commission |
author_facet |
European Commission Baca-González, Victoria Asensio-Calavia, Patricia González-Acosta, Sergio Morales-delaNuez, Antonio Pérez de Lastra, José Manuel |
format |
artículo |
topic_facet |
Anti-infective agents Immune therapy Vaccine Antibodies Epitope Peptide |
author |
Baca-González, Victoria Asensio-Calavia, Patricia González-Acosta, Sergio Morales-delaNuez, Antonio Pérez de Lastra, José Manuel |
author_sort |
Baca-González, Victoria |
title |
Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19? |
title_short |
Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19? |
title_full |
Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19? |
title_fullStr |
Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19? |
title_full_unstemmed |
Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19? |
title_sort |
can immunization of hens provide oral-based therapeutics against covid-19? |
publisher |
Multidisciplinary Digital Publishing Institute |
publishDate |
2020-08-28 |
url |
http://hdl.handle.net/10261/219966 http://dx.doi.org/10.13039/501100000780 http://dx.doi.org/10.13039/501100004837 |
work_keys_str_mv |
AT bacagonzalezvictoria canimmunizationofhensprovideoralbasedtherapeuticsagainstcovid19 AT asensiocalaviapatricia canimmunizationofhensprovideoralbasedtherapeuticsagainstcovid19 AT gonzalezacostasergio canimmunizationofhensprovideoralbasedtherapeuticsagainstcovid19 AT moralesdelanuezantonio canimmunizationofhensprovideoralbasedtherapeuticsagainstcovid19 AT perezdelastrajosemanuel canimmunizationofhensprovideoralbasedtherapeuticsagainstcovid19 |
_version_ |
1777669874930155520 |